Prevention and Management of Infusion-Associated Reactions in the Comparison of Alemtuzumab and Rebif(®) Efficacy in Multiple Sclerosis (CARE-MS) Program.
Int J MS Care
; 17(4): 191-8, 2015.
Article
en En
| MEDLINE
| ID: mdl-26300705
Texto completo:
1
Banco de datos:
MEDLINE
Tipo de estudio:
Guideline
/
Risk_factors_studies
Idioma:
En
Año:
2015
Tipo del documento:
Article